Immunogenicity of an adjuvanted, combination inactivated rabies-vectored, Lassa fever vaccine in healthy adults: interim results of a first-in-human Phase 1 trial
Ortiz, J. R.; Kurup, D.; Kaufman, A. C.; Ben Hamed, S.; LaRocco, A.; Lyke, K. E.; Litts, S.; Datta, S.; Liang, Y.; McGilvray, M. F.; Losignor, J.; Oshinsky, J. J.; Palmer, K. V.; Mayo-Johnson, I. P.; Scher, G.; Balakumar, U.; Chandwani, A.; Rapaka, R. R.; Deming, M. E.; Chua, J. V.; Wirblich, C.; Chen, W. H.; Neuzil, K. M.; Pasetti, M.; Schnell, M.
Show abstract
We conducted a randomized, controlled Phase 1 trial of an inactivated rabies virus-vectored Lassa virus glycoprotein complex (GPC) vaccine (LASSARAB) formulated with a synthetic oil-in-water TLR-4 agonist adjuvant (3D-6acyl PHAD-SE). In dose-escalating cohorts, participants received two intramuscular doses of LASSARAB containing 700 (n=15), 1400 (n=15), or 2800 (n=14) relative units of antigen, as quantified by ELISA using recombinant GPC as a standard, or a licensed rabies vaccine control (n=10), administered 28 days apart. This interim analysis reports the primary objective of safety evaluation and the secondary objective of immunogenicity assessment through Day 61. All doses were well tolerated. After two doses, Lassa GPC ELISA seroconversion rates were 100% in all LASSARAB groups and 0% in the control group. Rabies glycoprotein ELISA seroconversion and neutralizing antibody seroprotection were both 100% across all groups, including controls. This first-in-human study demonstrates that LASSARAB+3D-6acyl PHAD-SE is a well-tolerated, highly immunogenic, combination vaccine, supporting further clinical evaluation. ClinicalTrials.gov identifier: NCT06546709.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam 98%
- Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial 97%
- Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-Blinded, Noninferiority Study 96%
Similar papers in this journal
- A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 98%
- Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial 97%
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report 97%
Similar papers in this journal
- Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 years 96%
- Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar 95%
- Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patients 92%
Similar papers in this journal
- Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report 96%
- A Gamma-adapted recombinant subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection. 95%
- Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.